About Us

The last few years have seen dramatic growth in outsourcing to India in all areas of technology. The trend has been particularly noticeable in the pharmaceuticals sector. Leading pharmaceutical firms across the world are increasingly turning to India to outsource processes and solutions as part of their efforts to bring down the price of drugs. Drug makers operating in US could save at least 60 per cent in producing new drugs by outsourcing R&D and other services to India; it is estimated. In this way, we come in to picture. DELPHIS PHARMA is pharma house which offers third-party manufacturing for domestic and export formulations with optimum quality at most competitive rates with excellent backup team to ensure on Schedule delivery.

Dephis Pharma are in to Contract – Manufacturing of Tablets, Capsules, Injectables, Ointments, Generics, Drops Eye / Ears, Creams, Shampoos, Cosmetics, Herbal Preparations, Hard Gelatine, Soft Gelatine, Dry Syrup, Lotions, Protein Supplements, Powders, Dietary supplement, Soaps, Formulations & Contract Manufacturing. and are going from strength, since 5 years of commitment and sound knowledge of good Contract – manufacturing practices.

Delphis Pharma is in Contract – Manufacturer of pharmaceuticals formulation and growing from strength since 5 years of commitment and sound knowledge of good Contract – manufacturing practices with WHO GMP Standards, Schedule ‘M’ Compliance with a knowledge to provide innovative healthcare products. “Higher Quality, attractive and eye catching packing materials and prompt after sales service” is the basic philosophy & knowledge at “DELPHIS PHARMA”.

According to reports:

  •   India has a good shot at cornering at least one-fifth of outsourcing opportunity in the global pharmaceutical industry worth $48 billion.
  •   Cost saving is not the primary reason why pharmaceutical companies outsource. The size of pharmaceutical outsourcing is also small compared to that in BPO and IT. Pharmaceutical R&D outsourcing represents no more than US$3-4 billion in US.
  •   Yet, the increase in R & D outsourcing in the pharmaceutical and biotechnology sectors represents a significant development.
  •   Pharmaceutical and biotechnology companies are now convinced that networked R&D is the way to reduce costs and increase productivity.